Fulgent Genetics, Inc. (FLGT)
NASDAQ: FLGT · Real-Time Price · USD
20.12
+0.42 (2.13%)
At close: May 12, 2025, 4:00 PM
19.81
-0.31 (-1.54%)
After-hours: May 12, 2025, 7:07 PM EDT
Fulgent Genetics Revenue
Fulgent Genetics had revenue of $73.46M in the quarter ending March 31, 2025, with 13.92% growth. This brings the company's revenue in the last twelve months to $292.45M, up 1.71% year-over-year. In the year 2024, Fulgent Genetics had annual revenue of $283.47M, down -1.99%.
Revenue (ttm)
$292.45M
Revenue Growth
+1.71%
P/S Ratio
2.10
Revenue / Employee
$222,733
Employees
1,313
Market Cap
612.53M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 283.47M | -5.74M | -1.99% |
Dec 31, 2023 | 289.21M | -329.76M | -53.27% |
Dec 31, 2022 | 618.97M | -373.62M | -37.64% |
Dec 31, 2021 | 992.58M | 570.87M | 135.37% |
Dec 31, 2020 | 421.71M | 389.18M | 1,196.46% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
FLGT News
- 10 days ago - Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Fulgent Reports First Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025 - Business Wire
- 5 weeks ago - Stock Picks From Seeking Alpha's March 2025 New Analysts - Seeking Alpha
- 7 weeks ago - Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy - Seeking Alpha
- 2 months ago - Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript - Seeking Alpha
- 2 months ago - Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 3 months ago - Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025 - Business Wire